Concord Medical Announces Obtaining Large Medical Equipment Procurement License For Its Proton Therapy Equipment
Concord Medical Announces Obtaining Large Medical Equipment Procurement License For Its Proton Therapy Equipment
Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.
中國專門從事癌症治療、研究、教育和預防的醫療保健提供商協和醫療服務控股有限公司（「協和醫療」 或 「公司」）（紐約證券交易所代碼：CCM）今天宣佈，該公司提供綜合癌症護理服務的中國子公司廣州協和癌症中心（「廣州醫院」）已獲得質子設備的大型醫療設備採購許可證（「許可證」）。
As previously disclosed in the Company's annual report for the fiscal year ended December 31, 2023, Guangzhou Hospital has completed the installment of the proton equipment in September 2020 and commenced its clinical trial in November 2022. Guangzhou Hospital has also subsequently submitted the application for the License for such proton equipment, planning to offer proton therapy treatment services at its proton center. On September 14, 2024, the National Health Commission of the PRC announced to grant approval to Guangzhou Hospital's application for the License. Guangzhou Hospital plans to start its proton therapy treatment services at its earliest convenience after necessary preparations.
正如公司此前在截至2023年12月31日的財政年度的年度報告中披露的那樣，廣州醫院已於2020年9月完成質子設備的分期付款，並於2022年11月開始臨床試驗。隨後，廣州醫院也提交了此類質子設備的許可證申請，計劃在其質子中心提供質子治療服務。2024年9月14日，中華人民共和國國家衛生委員會宣佈批准廣州醫院的許可證申請。廣州醫院計劃在必要準備後儘早啓動質子治療服務。
